{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:59:58Z","timestamp":1792519198915,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1038\/nrrheum.2017.98","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T04:19:04Z","timestamp":1499314744000},"page":"476-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":170,"title":["Visual loss and other cranial ischaemic complications in giant cell arteritis"],"prefix":"10.1038","volume":"13","author":[{"given":"Alessandra","family":"Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muratore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Pipitone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Boiardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"key":"BFnrrheum201798_CR1","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.160466","volume":"43","author":"MA Gonzalez-Gay","year":"2016","unstructured":"Gonzalez-Gay, M. A., Castaneda, S. & Llorca, J. Giant cell arteritis: visual loss is our major concern. J. Rheumatol. 43, 1458\u20131461 (2016).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201798_CR2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","volume":"41","author":"MC Cid","year":"1998","unstructured":"Cid, M. C.  et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 41, 26\u201332 (1998).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201798_CR3","first-page":"2624","volume":"27","author":"G Haugeberg","year":"2000","unstructured":"Haugeberg, G., Paulsen, P. Q. & Bie, R. B. Temporal arteritis in Vest Agder County in southern Norway: incidence and clinical findings. J. Rheumatol. 27, 2624\u20132627 (2000).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201798_CR4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","volume":"372","author":"C Salvarani","year":"2008","unstructured":"Salvarani, C., Cantini, F. & Hunder, G. G. Polymyalgia rheumatica and giant-cell arteritis. Lancet 372, 234\u2013245 (2008).","journal-title":"Lancet"},{"key":"BFnrrheum201798_CR5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","volume":"347","author":"C Salvarani","year":"2002","unstructured":"Salvarani, C., Cantini, F., Boiardi, L & Hunder, G. GPolymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med. 347, 261\u2013271 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201798_CR6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0140-6736(00)86182-6","volume":"231","author":"GH Jennings","year":"1938","unstructured":"Jennings, G. H. Arteritis of the temporal vessels. Lancet 231, 424\u2013428 (1938).","journal-title":"Lancet"},{"key":"BFnrrheum201798_CR7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.1957.02970450023007","volume":"163","author":"NC Birkhead","year":"1957","unstructured":"Birkhead, N. C., Wagener, H. P. & Shick, R. M. Treatment of temporal arteritis with adrenal corticosteroids; results in fifty-five cases in which lesion was proved at biopsy. J. Am. Med. Assoc. 163, 821\u2013827 (1957).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnrrheum201798_CR8","first-page":"300","volume":"47","author":"GM Bruce","year":"1949","unstructured":"Bruce, G. M. Temporal arteritis as a cause of blindness; review of literature and report of a case. Trans. Am. Ophthalmol. Soc. 47, 300\u2013316 (1949).","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"BFnrrheum201798_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/qjmed\/15.57.47","volume":"15","author":"WT Cooke","year":"1946","unstructured":"Cooke, W. T., Cloake, P. C., Govan, A. D. & Colbeck, J. C. Temporal arteritis; a generalized vascular disease. Q. J. Med. 15, 47\u201375 (1946).","journal-title":"Q. J. Med."},{"key":"BFnrrheum201798_CR10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0161-6420(93)31608-8","volume":"100","author":"PD Aiello","year":"1993","unstructured":"Aiello, P. D., Trautmann, J. C., McPhee, T. J., Kunselman, A. R. & Hunder, G. G. Visual prognosis in giant cell arteritis. Ophthalmology 100, 550\u2013555 (1993).","journal-title":"Ophthalmology"},{"key":"BFnrrheum201798_CR11","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0161-6420(94)31102-X","volume":"101","author":"GT Liu","year":"1994","unstructured":"Liu, G. T., Glaser, J. S., Schatz, N. J. & Smith, J. L. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 101, 1779\u20131785 (1994).","journal-title":"Ophthalmology"},{"key":"BFnrrheum201798_CR12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0002-9394(99)80192-5","volume":"125","author":"SS Hayreh","year":"1998","unstructured":"Hayreh, S. S., Podhajsky, P. A. & Zimmerman, B. Ocular manifestations of giant cell arteritis. Am. J. Ophthalmol. 125, 509\u2013520 (1998).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrrheum201798_CR13","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.20171","volume":"50","author":"G Nesher","year":"2004","unstructured":"Nesher, G.  et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 50, 1332\u20131337 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201798_CR14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/art.1780310607","volume":"31","author":"EB Machado","year":"1988","unstructured":"Machado, E. B.  et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950\u20131985. Arthritis Rheum. 31, 745\u2013749 (1988).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201798_CR15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","volume":"48","author":"C Salvarani","year":"2009","unstructured":"Salvarani, C.  et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford) 48, 250\u2013253 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201798_CR16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3899\/jrheum.140188","volume":"42","author":"AG Singh","year":"2015","unstructured":"Singh, A. G.  et al. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J. Rheumatol. 42, 309\u2013315 (2015).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201798_CR17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/BF02229646","volume":"15","author":"G Nesher","year":"1996","unstructured":"Nesher, G., Rubinow, A. & Sonnenblick, M. Trends in the clinical presentation of temporal arteritis in Israel: reflection of increased physician awareness. Clin. Rheumatol. 15, 483\u2013485 (1996).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201798_CR18","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3899\/jrheum.151135","volume":"43","author":"E Liozon","year":"2016","unstructured":"Liozon, E.  et al. Risk factors for permanent visual loss in biopsy-proven giant cell arteritis: a study of 339 patients. J. Rheumatol. 43, 1393\u20131399 (2016).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201798_CR19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F","volume":"42","author":"A Brack","year":"1999","unstructured":"Brack, A., Martinez-Taboada, V., Stanson, A., Goronzy, J. J. & Weyand, C. M. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 42, 311\u2013317 (1999).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201798_CR20","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z","volume":"41","author":"MA Gonzalez-Gay","year":"1998","unstructured":"Gonzalez-Gay, M. A.  et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 41, 1497\u20131504 (1998).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201798_CR21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/rheumatology\/ken480","volume":"48","author":"CT Berger","year":"2009","unstructured":"Berger, C. T., Wolbers, M., Meyer, P., Daikeler, T. & Hess, C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology (Oxford) 48, 258\u2013261 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201798_CR22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MD.0b013e3181af4518","volume":"88","author":"MA Gonzalez-Gay","year":"2009","unstructured":"Gonzalez-Gay, M. A.  et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 88, 227\u2013235 (2009).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrrheum201798_CR23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/jnnp-2014-307614","volume":"86","author":"M Samson","year":"2015","unstructured":"Samson, M.  et al. Stroke associated with giant cell arteritis: a population-based study. J. Neurol. Neurosurg. Psychiatry. 86, 216\u2013221 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"BFnrrheum201798_CR24","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s00296-013-2814-0","volume":"33","author":"T Zenone","year":"2013","unstructured":"Zenone, T. & Puget, M. Characteristics of cerebrovascular accidents at time of diagnosis in a series of 98 patients with giant cell arteritis. Rheumatol. Int. 33, 3017\u20133023 (2013).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum201798_CR25","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1097\/MD.0000000000000265","volume":"93","author":"D Lariviere","year":"2014","unstructured":"Lariviere, D.  et al. Extra- and intracranial cerebral vasculitis in giant cell arteritis. Medicine (Baltimore) 93, e265 (2014).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrrheum201798_CR26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/M12-3046","volume":"160","author":"G Tomasson","year":"2014","unstructured":"Tomasson, G.  et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann. Intern. Med. 160, 73\u201380 (2014).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum201798_CR27","doi-asserted-by":"crossref","first-page":"e0149579","DOI":"10.1371\/journal.pone.0149579","volume":"11","author":"A Lo Gullo","year":"2016","unstructured":"Lo Gullo, A.  et al. Venous thromboembolism and cerebrovascular events in patients with giant cell arteritis: a population-based retrospective cohort study. PLoS ONE 11, e0149579 (2016).","journal-title":"PLoS ONE"},{"key":"BFnrrheum201798_CR28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-642-11852-4_12","volume-title":"Ischemic Optic Neuropathies","author":"SS Hayreh","year":"2011","unstructured":"Hayreh, S. S. in Ischemic Optic Neuropathies 199\u2013226 (Springer-Verlag, 2011)."},{"key":"BFnrrheum201798_CR29","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1056\/NEJMra1413352","volume":"372","author":"V Biousse","year":"2015","unstructured":"Biousse, V. & Newman, N. Ischemic optic neuropathies. N. Engl. J. Med. 372, 2428\u20132436 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201798_CR30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00005792-200009000-00001","volume":"79","author":"MA Gonzalez-Gay","year":"2000","unstructured":"Gonzalez-Gay, M. A.  et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 79, 283\u2013292 (2000).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrrheum201798_CR31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0002-9394(99)80193-7","volume":"125","author":"SS Hayreh","year":"1998","unstructured":"Hayreh, S. S., Podhajsky, P. A. & Zimmerman, B. Occult giant cell arteritis: ocular manifestations. Am. J. Ophthalmol. 125, 521\u2013526 (1998).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrrheum201798_CR32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/MD.0b013e3181908e96","volume":"87","author":"R Solans-Laqu\u00e9","year":"2008","unstructured":"Solans-Laqu\u00e9, R.  et al. Stroke and multi-infarct dementia as presenting symptoms of giant cell arteritis. Report of 7 cases and review of the literature. Medicine (Baltimore) 87, 335\u2013344 (2008).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrrheum201798_CR33","first-page":"2356","volume":"32","author":"K Pfadenhauer","year":"2005","unstructured":"Pfadenhauer, K., Esser, M. & Berger, K. Vertebrobasilar ischemia and structural abnormalities of the vertebral arteries in active temporal arteritis and polymyalgia rheumatica \u2014 an ultrasonographic case-control study. J. Rheumatol. 32, 2356\u20132360 (2005).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201798_CR34","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archneur.1972.00490170010003","volume":"27","author":"IM Wilkinson","year":"1972","unstructured":"Wilkinson, I. M. & Russel, R. W. Arteries of head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch. Neurol. 27, 378\u2013391 (1972).","journal-title":"Arch. Neurol."},{"key":"BFnrrheum201798_CR35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/art.22359","volume":"55","author":"C Salvarani","year":"2006","unstructured":"Salvarani, C., Giannini, C., Miller, D. V. & Hunder, G. G. Giant cell arteritis: involvement of intracranial arteries. Arthritis Rheum. 55, 985\u2013989 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201798_CR36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00019052-200402000-00006","volume":"17","author":"JC Rucker","year":"2004","unstructured":"Rucker, J. C., Biousse, V. & Newman, N. J. Ischemic optic neuropathies. Curr. Opin. Neurol. 17, 27\u201335 (2004).","journal-title":"Curr. Opin. Neurol."},{"key":"BFnrrheum201798_CR37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0002-9343(01)00770-7","volume":"111","author":"E Liozon","year":"2001","unstructured":"Liozon, E.  et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am. J. Med. 111, 211\u2013217 (2001).","journal-title":"Am. J. Med."},{"key":"BFnrrheum201798_CR38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.md.0000119761.27564.c9","volume":"83","author":"G Nesher","year":"2004","unstructured":"Nesher, G.  et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine (Baltimore) 83, 114\u2013122 (2004).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrrheum201798_CR39","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/rheumatology\/keu329","volume":"54","author":"F Muratore","year":"2015","unstructured":"Muratore, F.  et al. Large vessel giant cell arteritis: a cohort study. Rheumatology (Oxford) 54, 463\u2013470 (2015).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201798_CR40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.md.0000145369.25558.b5","volume":"83","author":"MA Gonzalez-Gay","year":"2004","unstructured":"Gonzalez-Gay, M. A.  et al. Influence of traditional risk factors of atherosclerosis in the development of severe complications of giant cell arteritis. Medicine (Baltimore) 83, 342\u2013347 (2004).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrrheum201798_CR41","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3899\/jrheum.151033","volume":"43","author":"M Saleh","year":"2016","unstructured":"Saleh, M., Turesson, C., Englund, M., Merkel, P. A. & Mohammad, A. J. Visual complications in patients with biopsy-proven giant cell arteritis: a population-based study. J. Rheumatol. 43, 1559\u20131565 (2016).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201798_CR42","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.md.0000180043.19285.54","volume":"84","author":"MA Gonzalez-Gay","year":"2005","unstructured":"Gonzalez-Gay, M. A.  et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore) 84, 277\u2013290 (2005).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrrheum201798_CR43","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000030185.67510.C0","volume":"106","author":"MC Cid","year":"2002","unstructured":"Cid, M. C.  et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 106, 1664\u20131671 (2002).","journal-title":"Circulation"},{"key":"BFnrrheum201798_CR44","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1161\/01.CIR.0000066907.83923.32","volume":"107","author":"J Hern\u00e1ndez-Rodr\u00edguez","year":"2003","unstructured":"Hern\u00e1ndez-Rodr\u00edguez, J.  et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis. Angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 107, 2428\u20132434 (2003).","journal-title":"Circulation"},{"key":"BFnrrheum201798_CR45","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/sarh.2002.50025","volume":"33","author":"MA Gonzalez-Gay","year":"2003","unstructured":"Gonzalez-Gay, M. A., Amoli, M. M., Garcia-Porrua, C. & Ollier, W. E. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin. Arthritis Rheum. 33, 38\u201348 (2003).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum201798_CR46","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ajhg.2015.02.009","volume":"96","author":"FD Carmona","year":"2015","unstructured":"Carmona, F. D.  et al. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. Am. J. Hum. Genet. 96, 565\u2013580 (2015).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrrheum201798_CR47","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1002\/art.22922","volume":"56","author":"C Salvarani","year":"2007","unstructured":"Salvarani, C.  et al. PIA1\/A2 polymorphism of the platelet glycoprotein receptor IIIA and the risk of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 56, 3502\u20133508 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201798_CR48","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1161\/01.ATV.19.4.1142","volume":"19","author":"D Feng","year":"1999","unstructured":"Feng, D.  et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 19, 1142\u20131147 (1999).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrrheum201798_CR49","first-page":"1737","volume":"32","author":"B Rueda","year":"2005","unstructured":"Rueda, B.  et al. A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J. Rheumatol. 32, 1737\u20131741 (2005).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201798_CR50","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.3899\/jrheum.100362","volume":"37","author":"L Rodr\u00edguez-Rodr\u00edguez","year":"2010","unstructured":"Rodr\u00edguez-Rodr\u00edguez, L.  et al. Influence of CD40 rs1883832 polymorphism in susceptibility to and clinical manifestations of biopsy-proven giant cell arteritis. J. Rheumatol. 37, 2076\u20132080 (2010).","journal-title":"J. Rheumatol."},{"issue":"6 Suppl. 36","key":"BFnrrheum201798_CR51","first-page":"S18","volume":"22","author":"MA Gonzalez-Gay","year":"2004","unstructured":"Gonzalez-Gay, M. A.  et al. Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and polymyalgia rheumatica. Clin. Exp. Rheumatol. 22 (6 Suppl. 36), S18\u2013S20 (2004).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201798_CR52","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/1529-0131(199804)41:4<623::AID-ART9>3.0.CO;2-6","volume":"41","author":"M Kaiser","year":"1998","unstructured":"Kaiser, M., Weyand, C. M., Bj\u00f6rnsson, J. & Goronzy, J. J. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum. 41, 623\u2013633 (1998).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201798_CR53","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/rheumatology\/ken012","volume":"47","author":"D Makkuni","year":"2008","unstructured":"Makkuni, D.  et al. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology (Oxford) 47, 488\u2013490 (2008).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201798_CR54","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.084947","volume":"68","author":"D Chatelain","year":"2009","unstructured":"Chatelain, D.  et al. Pathological features of temporal arteritis in patients with giant cell arteritis presenting with permanent visual loss. Ann. Rheum. Dis. 68, 84\u201388 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201798_CR55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaut.2016.03.005","volume":"69","author":"F Muratore","year":"2016","unstructured":"Muratore, F.  et al. Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis. J. Autoimmun. 69, 94\u2013101 (2016).","journal-title":"J. Autoimmun."},{"key":"BFnrrheum201798_CR56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/sarh.2001.23499","volume":"31","author":"G Espinosa","year":"2001","unstructured":"Espinosa, G.  et al. Antiphospholipid antibodies and thrombophilic factors in giant cell arteritis. Semin. Arthritis. Rheum. 31, 12\u201320 (2001).","journal-title":"Semin. Arthritis. Rheum."},{"key":"BFnrrheum201798_CR57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/sarh.2001.16650","volume":"30","author":"MA Gonzalez-Gay","year":"2001","unstructured":"Gonzalez-Gay, M. A., Garcia-Porrua, C., Llorca, J., Gonzalez-Louzao, C. & Rodriguez-Ledo, P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin. Arthritis Rheum. 30, 249\u2013256 (2001).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum201798_CR58","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/acr.22736","volume":"68","author":"F Muratore","year":"2016","unstructured":"Muratore, F.  et al. Histopathologic findings of patients with biopsy-negative giant cell arteritis compared to those without arteritis: a population-based study. Arthritis Care Res. (Hoboken) 68, 865\u2013870 (2016).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum201798_CR59","doi-asserted-by":"crossref","first-page":"987","DOI":"10.7326\/0003-4819-120-12-199406150-00003","volume":"120","author":"AA Achkar","year":"1994","unstructured":"Achkar, A. A., Lie, J. T., Hunder, G. G., O'Fallon, W. M. & Gabriel, S. E. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann. Intern. Med. 120, 987\u2013992 (1994).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum201798_CR60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semarthrit.2006.12.005","volume":"37","author":"J Narv\u00e1ez","year":"2007","unstructured":"Narv\u00e1ez, J.  et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin. Arthritis. Rheum. 37, 13\u201339 (2007).","journal-title":"Semin. Arthritis. Rheum."},{"key":"BFnrrheum201798_CR61","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/jclinpath-2012-200870","volume":"65","author":"D Bury","year":"2012","unstructured":"Bury, D., Joseph, J. & Dawson, T. P. Does preoperative steroid treatment affect the histology in giant cell (cranial) arteritis? J. Clin. Pathol. 65, 1138\u20131140 (2012).","journal-title":"J. Clin. Pathol."},{"key":"BFnrrheum201798_CR62","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar, C.  et al. EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. Dis. 68, 318\u2013323 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201798_CR63","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/keq039a","volume":"49","author":"B Dasgupta","year":"2010","unstructured":"Dasgupta, B.  et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford) 49, 1594\u20131597 (2010).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201798_CR64","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.revmed.2015.12.015","volume":"37","author":"B Bienvenu","year":"2016","unstructured":"Bienvenu, B.  et al. Management of giant cell arteritis: recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev. Med. Interne 37, 154\u2013165 (2016).","journal-title":"Rev. Med. Interne"},{"key":"BFnrrheum201798_CR65","doi-asserted-by":"crossref","first-page":"613","DOI":"10.7326\/0003-4819-82-5-613","volume":"82","author":"GG Hunder","year":"1975","unstructured":"Hunder, G. G.  et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann. Intern. Med. 82, 613\u2013618 (1975).","journal-title":"Ann. Intern. Med."},{"issue":"2 Suppl. 89","key":"BFnrrheum201798_CR66","first-page":"S103","volume":"33","author":"P Patil","year":"2015","unstructured":"Patil, P.  et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin. Exp. Rheumatol. 33 (2 Suppl. 89), S103\u2013S106 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201798_CR67","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/rheumatology\/kev289","volume":"55","author":"AP Diamantopoulos","year":"2016","unstructured":"Diamantopoulos, A. P., Haugeberg, G., Lindland, A. & Myklebust, G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford) 55, 66\u201370 (2016).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201798_CR68","first-page":"1484","volume":"27","author":"P Chevalet","year":"2000","unstructured":"Chevalet, P.  et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients. J. Rheumatol. 27, 1484\u20131491 (2000).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201798_CR69","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","volume":"54","author":"M Mazlumzadeh","year":"2006","unstructured":"Mazlumzadeh, M.  et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 54, 3310\u20133318 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201798_CR70","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0161-6420(03)00228-8","volume":"110","author":"SS Hayreh","year":"2003","unstructured":"Hayreh, S. S. & Zimmerman, B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 110, 1204\u20131215 (2003).","journal-title":"Ophthalmology"},{"key":"BFnrrheum201798_CR71","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0161-6420(97)30222-X","volume":"104","author":"WT Cornblath","year":"1997","unstructured":"Cornblath, W. T. & Eggenberger, E. R. Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology 104, 854\u2013858 (1997).","journal-title":"Ophthalmology"},{"key":"BFnrrheum201798_CR72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1034\/j.1600-0420.2002.800403.x","volume":"80","author":"SS Hayreh","year":"2002","unstructured":"Hayreh, S. S., Zimmerman, B. & Kardon, R. H. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol. Scand. 80, 355\u2013367 (2002).","journal-title":"Acta Ophthalmol. Scand."},{"key":"BFnrrheum201798_CR73","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2005.01.036","volume":"112","author":"H Danesh-Meyer","year":"2005","unstructured":"Danesh-Meyer, H., Savino, P. J. & Gamble, G. G. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 112, 1098\u20131103 (2005).","journal-title":"Ophthalmology"},{"key":"BFnrrheum201798_CR74","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/art.21075","volume":"53","author":"C Salvarani","year":"2005","unstructured":"Salvarani, C.  et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 53, 293\u2013297 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201798_CR75","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1136\/bjo.85.9.1061","volume":"85","author":"CC Chan","year":"2001","unstructured":"Chan, C. C., Paine, M. & O'Day, J. Steroid management in giant cell arteritis. Br. J. Ophthalmol. 85, 1061\u20131064 (2001).","journal-title":"Br. J. Ophthalmol."},{"key":"BFnrrheum201798_CR76","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/bjo.83.7.796","volume":"83","author":"MJ Kupersmith","year":"1999","unstructured":"Kupersmith, M. J.  et al. Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy. Br. J. Ophthalmol. 83, 796\u2013801 (1999).","journal-title":"Br. J. Ophthalmol."},{"key":"BFnrrheum201798_CR77","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0161-6420(02)01775-X","volume":"110","author":"R Foroozan","year":"2003","unstructured":"Foroozan, R.  et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 110, 539\u2013542 (2003).","journal-title":"Ophthalmology"},{"key":"BFnrrheum201798_CR78","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/WNO.0b013e3182688218","volume":"32","author":"SS Hayreh","year":"2012","unstructured":"Hayreh, S. S. & Biousse, V. Treatment of acute visual loss in giant cell arteritis: should we prescribe high-dose intravenous steroids or just oral steroids? J. Neuroophthalmol. 32, 278\u2013287 (2012).","journal-title":"J. Neuroophthalmol."},{"key":"BFnrrheum201798_CR79","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger, P. M.  et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387, 1921\u20131927 (2016).","journal-title":"Lancet"},{"issue":"Suppl. 10","key":"BFnrrheum201798_CR80","first-page":"911","volume":"68","author":"JH Stone","year":"2016","unstructured":"Stone, J. H.  et al. Efficacy and safety of tocilizumab in patients with giant cell arteritis: primary and secondary outcomes from a phase 3, randomized, double-blind, placebo-controlled trial [abstract]. Arthritis Rheumatol. 68 (Suppl. 10), 911 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201798_CR81","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","volume":"46","author":"GS Hoffman","year":"2002","unstructured":"Hoffman, G. S.  et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 46, 1309\u20131318 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201798_CR82","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1002\/art.22141","volume":"54","author":"MS Lee","year":"2006","unstructured":"Lee, M. S., Smith, S. D., Galor, A. & Hoffman, G. S. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 54, 3306\u20133309 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201798_CR83","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4236\/ojra.2014.42017","volume":"4","author":"J Jeong","year":"2014","unstructured":"Jeong, J. & Barra, L. The use of anti-platelet &\/or anticoagulant agents in the prevention of large vessel vasculitis-associated ischemic complications: a meta-analysis. Open J. Rheumatol. Autoimmun. Dis. (OJRA) 4, 114\u2013123 (2014).","journal-title":"Open J. Rheumatol. Autoimmun. Dis. (OJRA)"},{"key":"BFnrrheum201798_CR84","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.autrev.2014.02.006","volume":"13","author":"VM Mart\u00ednez-Taboada","year":"2014","unstructured":"Mart\u00ednez-Taboada, V. M., L\u00f3pez-Hoyos, M., Narvaez, J. & Munoz-Cacho, P. Effect of antiplatelet\/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun. Rev. 13, 788\u2013794 (2014).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201798_CR85","first-page":"CD010453","volume":"3","author":"SP Mollan","year":"2014","unstructured":"Mollan, S. P., Sharrack, N., Burdon, M. A. & Denniston, A. K. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst. Rev. 3, CD010453 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrrheum201798_CR86","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3899\/jrheum.150143","volume":"43","author":"RS Alsolaimani","year":"2016","unstructured":"Alsolaimani, R. S.  et al. Severe intracranial involvement in giant cell arteritis: 5 cases and literature review. J. Rheumatol. 43, 648\u2013656 (2016).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201798_CR87","first-page":"240","volume":"78","author":"SS Hayreh","year":"1974","unstructured":"Hayreh, S. S. Anatomy and physiology of the optic nerve head. Trans. Am. Acad. Ophthalmol. Otolaryngol. 78, 240\u2013254 (1974).","journal-title":"Trans. Am. Acad. Ophthalmol. Otolaryngol."},{"key":"BFnrrheum201798_CR88","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.ophtha.2016.05.008","volume":"123","author":"JJ Chen","year":"2016","unstructured":"Chen, J. J.  et al. Evaluating the incidence of arteritic ischemic optic neuropathy and other causes of vision loss from giant cell arteritis. Ophthalmology 123, 1999\u20132003 (2016).","journal-title":"Ophthalmology"},{"key":"BFnrrheum201798_CR89","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/hrt.2004.037481","volume":"91","author":"JG Ray","year":"2005","unstructured":"Ray, J. G., Mamdani, M. M. & Geerts, W. H. Giant cell arteritis and cardiovascular disease in older adults. Heart 91, 324\u2013328 (2005).","journal-title":"Heart"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2017.98.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2017.98","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrrheum.2017.98","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2017.98.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:42:48Z","timestamp":1684471368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2017.98"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":89,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["BFnrrheum201798"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2017.98","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,6]]},"assertion":[{"value":"6 July 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}